Last reviewed · How we verify

Prismocitrate 18 — Competitive Intelligence Brief

Prismocitrate 18 (Prismocitrate 18) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regional anticoagulant / Citrate-based anticoagulant. Area: Nephrology / Critical Care.

phase 3 Regional anticoagulant / Citrate-based anticoagulant Ionized calcium (Ca2+) Nephrology / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Prismocitrate 18 (Prismocitrate 18) — Vantive Health LLC. Prismocitrate 18 is a citrate-based anticoagulant used in regional citrate anticoagulation (RCA) for extracorporeal therapies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prismocitrate 18 TARGET Prismocitrate 18 Vantive Health LLC phase 3 Regional anticoagulant / Citrate-based anticoagulant Ionized calcium (Ca2+)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regional anticoagulant / Citrate-based anticoagulant class)

  1. Vantive Health LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prismocitrate 18 — Competitive Intelligence Brief. https://druglandscape.com/ci/prismocitrate-18. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: